The glycomic therapeutics market in Asia Pacific is expected to grow from US$ 12.95 billion in 2022 to US$ 34.59 billion by 2028; it is estimated to grow at a CAGR of 17.8% from 2022 to 2028.

Wide Applications of Glycomics in Therapeutics to Provide Lucrative Opportunities for Market Growth

Glycomics is a novel method for creating medicines. It draws on the knowledge that glycans serve as the primary means of altering numerous molecules in biological systems. This alteration provides those molecules with their complete, functional form. Glycans are found in most top-selling biologics and half of the therapeutic proteins, including antibodies against COVID-19. Glycans of these proteins have been tailored to improve their effectiveness, lower the dosages required, and lessen negative effects. For instance, understanding the biological functions of glycans has led to their inclusion as essential ingredients in medications for the treatment of diabetes, the prevention of blood clotting, and the improvement of in vitro fertilization. Changes in the glycans on a microbe’s surface are frequently connected to the microorganisms’ resistance to popular medications. This property is used for detecting particular glycans in infection samples, disabling the protective biofilms formed by the infecting bacteria, and weakening the glycan-rich cell walls of microorganisms. More than 130 uncommon genetic illnesses, many of which are fatal in childhood, are brought on by errors. Understanding the glycans responsible for a few of these problems has helped develop therapies. Since glycans can play a crucial role in studying attacks of bacteria and viruses on the immune systems of humans, they are employed in vaccinations. Additionally, recent research on SARS-CoV-2, which causes COVID-19, has shown infection pathways that depend on the virus’s usage of human glycans. Glycomics has the potential to bring new perspectives to precision medicine, which is currently dominated by genetic and proteomic tools. Therefore, the high adoption of glycomics in various therapeutic areas would propel the demand for these techniques in the coming years. Nonetheless, ongoing research and developments and clinical advancements in the field of therapeutics are expected to create lucrative growth opportunities for the glycomics therapeutics market during the forecast period.

Market Overview

Asia Pacific (APAC) is the fastest-growing market for glycomic therapeutics. The Asia Pacific glycomics therapeutics market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. Asia Pacific is likely to account for ~11.89% share of the global glycomic therapeutics market in 2022 owing to the improving government support in countries, collaboration of research organizations, rising glycomics research institutes, and advancing healthcare infrastructure. Therefore, the region offers several opportunities for the glycomic therapeutics market players to grow during the forecast period.

Asia Pacific Glycomic Therapeutics Market Revenue and Forecast to 2028 (US$ Billion)

Asia Pacific Glycomic Therapeutics Market Segmentation

The Asia Pacific glycomic therapeutics market is segmented on the basis of class, structure, indications, mode of action, and country.

Based on class, the Asia Pacific glycomic therapeutics market is bifurcated into isolated and synthetic. The synthetic segment registered a larger market share in 2022. Based on structure, the Asia Pacific glycomic therapeutics market is segmented into glycoproteins, targeting sialic acid, proteoglycans, targeting glycosaminoglycans, glycosylphosphatidylinositol (GPI)-anchored proteins & heparin based glycans, targeting glycosphingolipids, and others. The glycoproteins segment held the largest market share in 2022. Based on indications, the Asia Pacific glycomic therapeutics market is segmented into thrombosis & chemoprophylaxis, anaemia, anti-adhesive & anti-inflammatory, cataracts, gaucher’s disease, MPS-1 & IV, cancer, alzheimer’s disease, influenza type A & B, and others. The influenza type a & b segment held the largest market share in 2022. Based on mode of action, the Asia Pacific glycomic therapeutics market is segmented into inhibits neuraminidase, inhibits heparanase and selectins and blocks interactions between growth factors and heparan sulfate, erythropoietin & enzyme replacement therapy (ERT), tissue plasminogen activator, inhibits glucosylceramide synthase, interleukin 1 and 2 and 3, beta & gamma interferons, and others. The erythropoietin & enzyme replacement therapy (ERT) segment held the largest market share in 2022. Based on country, the Asia Pacific glycomic therapeutics market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the market in 2022. BioMarinPharmaceuticalInc.;GenzymeCorporation(Sanofi);BayerAG;Alzheon,Inc.;GlaxoSmithKline plc.; and F. Hoffmann-La Roche Ltd. are the leading companies operating in the glycomic therapeutics in Asia Pacific.

TABLE OF CONTENTS

1. Introduction
1.1 Study Scope
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Asia Pacific Glycomic Therapeutics Market – By Class
1.3.2 Asia Pacific Glycomic Therapeutics Market – By Structures
1.3.3 Asia Pacific Glycomic Therapeutics Market – By Indications
1.3.4 Asia Pacific Glycomic Therapeutics Market – By Mode of Action
1.3.5 Asia Pacific Glycomic Therapeutics Market – By Country
2. Asia Pacific Glycomic Therapeutics Market– Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Glycomic Therapeutics Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Asia Pacific – PEST Analysis
4.3 Expert Opinion
5. Asia Pacific Glycomic Therapeutics Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Wide Application in Various Disorders Followed by the Development of New Treatment Processes
5.1.2 Increasing Research and Development In the Field of Glycomic Therapeutics
5.2 Market Restraints
5.2.1 Shortage of Skilled Professionals and Lack of Research & Development laboratories in Developing Countries.
5.3 Market Opportunities
5.3.1 Wide Applications of Glycomics in Therapeutics
5.4 Future Trends
5.4.1 New Tools in Glycomics Research
5.5 Impact Analysis
6. Glycomic Therapeutics Market– Asia Pacific Analysis
6.1 Asia Pacific Glycomic Therapeutics Market Revenue Forecast and Analysis
6.1.1 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, (US$ Million)
7. Asia Pacific Glycomic Therapeutics Market Revenue and Forecast to 2028– by Class
7.1 Overview
7.2 Asia Pacific Glycomic Therapeutics Market, By Class 2022 & 2028 (%)
7.2.1 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million)
7.3 Isolated
7.3.1 Overview
7.3.2 Asia Pacific Isolated Revenue and Forecast to 2028 (US$ Million)
7.4 Synthetic
7.4.1 Overview
7.4.2 Asia Pacific Synthetic – Revenue and Forecast to 2028 (US$ Million)
8. Asia Pacific Glycomics Therapeutics Market Analysis and Forecasts To 2028 – By Indication
8.1 Overview
8.2 Asia Pacific Glycomics Market, By Indication 2022 & 2028 (%)
8.2.1 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)
8.3 Thrombosis and Chemoprophylaxis
8.3.1 Overview
8.3.2 Asia Pacific Thrombosis and chemoprophylaxis Revenue and Forecast to 2028 (US$ Million)
8.4 Anaemia
8.4.1 Overview
8.4.2 Asia Pacific Anaemia Revenue and Forecast to 2028 (US$ Million)
8.5 Anti-adhesive and Anti-inflammatory
8.5.1 Overview
8.5.2 Asia Pacific Anti-adhesive and Anti-inflammatory Revenue and Forecast to 2028 (US$ Million)
8.6 Cataract
8.6.1 Overview
8.6.2 Asia Pacific Cataract Revenue and Forecast to 2028 (US$ Million)
8.7 Gaucher’s diseases
8.7.1 Overview
8.7.2 Asia Pacific Gaucher’s diseases Revenue and Forecast to 2028 (US$ Million)
8.8 MPS-1 & IV
8.8.1 Overview
8.8.2 Asia Pacific MPS-1 & IV Revenue and Forecast to 2028 (US$ Million)
8.9 Cancer
8.9.1 Overview
8.9.2 Asia Pacific Cancer Revenue and Forecast to 2028 (US$ Million)
8.10 Alzheimer’s
8.10.1 Overview
8.10.2 Asia Pacific Alzheimer’s Revenue and Forecast to 2028 (US$ Million)
8.11 Influenza Type A and B
8.11.1 Overview
8.11.2 Asia Pacific Influenza Type A and B Revenue and Forecast to 2028 (US$ Million)
8.12 Others
8.12.1 Overview
8.12.2 Asia Pacific Others Revenue and Forecast to 2028 (US$ Million)
9. Asia Pacific Glycomic Therapeutics Market Revenue and Forecast to 2028 – by Structures
9.1 Overview
9.2 Asia Pacific Glycomic Therapeutics Market, By Structures 2022 & 2028 (%)
9.2.1 Asia Pacific: Glycomic Therapeutics Market, by Structures, 2019–2028 (US$ Million)
9.2.1.1 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)
9.2.1.2 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)
9.2.1.3 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)
9.2.1.4 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)
9.3 Glycoproteins
9.3.1 Overview
9.3.2 Asia Pacific Glycoproteins – Market Revenue and Forecast to 2028 (US$ Million)
9.4 Targeting Sialic Acid
9.4.1 Overview
9.4.2 Asia Pacific Targeting Sialic Acid – Market Revenue and Forecast to 2028 (US$ Million)
9.4.3 Zanamivir
9.4.3.1 Overview
9.4.3.2 Asia Pacific Zanamivir – Market Revenue and Forecast to 2028 (US$ Million)
9.4.4 Oseltamivir
9.4.4.1 Overview
9.4.4.2 Asia Pacific Oseltamivir – Market Revenue and Forecast to 2028 (US$ Million)
9.5 Proteoglycans
9.5.1 Overview
9.5.2 Asia Pacific Proteoglycans – Market Revenue and Forecast to 2028 (US$ Million)
9.6 Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin Based Glycans
9.6.1 Overview
9.6.2 Asia Pacific Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin Based Glycans – Market Revenue and Forecast to 2028 (US$ Million)
9.7 Targeting Glycosaminoglycans
9.7.1 Overview
9.7.2 Asia Pacific Targeting Glycosaminoglycans – Market Revenue and Forecast to 2028 (US$ Million)
9.7.3 Heparin
9.7.3.1 Overview
9.7.3.2 Asia Pacific Heparin – Market Revenue and Forecast to 2028 (US$ Million)
9.7.4 Hyaluronan (HA)
9.7.4.1 Overview
9.7.4.2 Asia Pacific Hyaluronan (HA)- Market Revenue and Forecast to 2028 (US$ Million)
9.7.5 Laronidase
9.7.5.1 Overview
9.7.5.2 Asia Pacific Laronidase – Market Revenue and Forecast to 2028 (US$ Million)
9.7.6 Galsulfase (Naglazyme)
9.7.6.1 Overview
9.7.6.2 Asia Pacific Galsulfase (Naglazyme) – Market Revenue and Forecast to 2028 (US$ Million)
9.7.7 Hyaluronidase (Cumulase)
9.7.7.1 Overview
9.7.7.2 Asia Pacific Hyaluronidase (Cumulase) – Market Revenue and Forecast to 2028 (US$ Million)
9.7.8 Others
9.7.8.1 Overview
9.7.8.2 Asia Pacific Others – Market Revenue and Forecast to 2028 (US$ Million)
9.8 Targeting Glycosphingolipids
9.8.1 Overview
9.8.2 Asia Pacific Targeting Glycosphingolipids – Market Revenue and Forecast to 2028 (US$ Million)
9.8.3 Imiglucerase (Cerezyme)
9.8.3.1 Overview
9.8.3.2 Asia Pacific Imiglucerase (Cerezyme)- Market Revenue and Forecast to 2028 (US$ Million)
9.8.3.3 Agalsidase (Fabrazyme)
9.8.3.3.1 Overview
9.8.3.3.2 Asia Pacific Agalsidase (Fabrazyme) – Market Revenue and Forecast to 2028 (US$ Million)
9.8.3.4 N-butyl-deoxynojirimycin (DNJ)
9.8.3.4.1 Overview
9.8.3.4.2 Asia Pacific N-butyl-deoxynojirimycin (DNJ) – Market Revenue and Forecast to 2028 (US$ Million)
9.8.4 Others
9.8.4.1 Overview
9.8.4.2 Asia Pacific Others – Market Revenue and Forecast to 2028 (US$ Million)
9.9 Others
9.9.1 Overview
9.9.2 Asia Pacific Others – Market Revenue and Forecast to 2028 (US$ Million)
9.9.3 Acarbose
9.9.3.1 Overview
9.9.3.2 Asia Pacific Acarbose – Market Revenue and Forecast to 2028 (US$ Million)
9.9.3.3 Alglucosidase Alfa (Myozyme)
9.9.3.3.1 Overview
9.9.3.3.2 Asia Pacific Alglucosidase Alfa (Myozyme) – Market Revenue and Forecast to 2028 (US$ Million)
9.9.3.4 Allosamidin
9.9.3.4.1 Overview
9.9.3.4.2 Asia Pacific Allosamidin – Market Revenue and Forecast to 2028 (US$ Million)
9.9.4 Others
9.9.4.1 Overview
9.9.4.2 Asia Pacific Others – Market Revenue and Forecast to 2028 (US$ Million)
10. Asia Pacific Glycomic Therapeutics Market Revenue and Forecast to 2028 – by Mode of Action
10.1 Overview
10.2 Asia Pacific Glycomic Therapeutics Market, By Mode of Action 2022 & 2028 (%)
10.2.1 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)
10.3 Inhibits Neuraminidase
10.3.1 Overview
10.3.2 Asia Pacific Inhibits Neuraminidase – Market Revenue and Forecast to 2028 (US$ Million)
10.4 Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate
10.4.1 Overview
10.4.2 Asia Pacific Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate – Market Revenue and Forecast to 2028 (US$ Million)
10.5 Erythropoietin And Enzyme Replacement Therapy (ERT)
10.5.1 Overview
10.5.2 Asia Pacific Erythropoietin And Enzyme Replacement Therapy (ERT) – Market Revenue and Forecast to 2028 (US$ Million)
10.6 Tissue Plasminogen Activator
10.6.1 Overview
10.6.2 Asia Pacific Tissue Plasminogen Activator – Market Revenue And Forecasts To 2028 (US$ Million)
10.7 Inhibits Glucosylceramide Synthase
10.7.1 Overview
10.7.2 Asia Pacific Inhibits Glucosylceramide Synthase – Market Revenue And Forecasts To 2028 (US$ Million)
10.8 Interleukin 1 And 2 And 3
10.8.1 Overview
10.8.2 Asia Pacific Interleukin 1 And 2 And 3- Market Revenue And Forecasts To 2028 (US$ Million)
10.9 Beta And Gamma Interferons
10.9.1 Overview
10.9.2 Asia Pacific Beta And Gamma Interferons- Market Revenue And Forecasts To 2028 (US$ Million)
10.10 Others
10.10.1 Overview
10.10.2 Asia Pacific Others- Market Revenue And Forecasts To 2028 (US$ Million)
11. Asia Pacific Glycomic Therapeutics Market Revenue and Forecasts to 2028 – Country Analysis
11.1 Asia Pacific Glycomic Therapeutics Market Revenue and Forecasts To 2028
11.1.1 Overview
11.1.2 Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Country (%)
11.1.2.1 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)
11.1.2.1.1 Overview
11.1.2.1.2 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)
11.1.2.1.3 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million)
11.1.2.1.4 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, by Structures, 2019–2028 (US$ Million)
11.1.2.1.4.1 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)
11.1.2.1.4.2 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)
11.1.2.1.4.3 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)
11.1.2.1.4.4 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)
11.1.2.1.5 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)
11.1.2.1.6 China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)
11.1.2.2 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)
11.1.2.2.1 Overview
11.1.2.2.2 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)
11.1.2.2.3 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million)
11.1.2.2.4 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, by Structures, 2019–2028 (US$ Million)
11.1.2.2.4.1 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)
11.1.2.2.4.2 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)
11.1.2.2.4.3 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)
11.1.2.2.4.4 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)
11.1.2.2.5 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)
11.1.2.2.6 Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)
11.1.2.3 India Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)
11.1.2.3.1 Overview
11.1.2.3.2 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)
11.1.2.3.3 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million)
11.1.2.3.4 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, by Structures, 2019–2028 (US$ Million)
11.1.2.3.4.1 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)
11.1.2.3.4.2 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)
11.1.2.3.4.3 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)
11.1.2.3.4.4 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)
11.1.2.3.5 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)
11.1.2.3.6 India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)
11.1.2.4 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)
11.1.2.4.1 Overview
11.1.2.4.2 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)
11.1.2.4.3 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million)
11.1.2.4.4 South Korea: Glycomic Therapeutics Market, by Structures, 2019–2028 (US$ Million)
11.1.2.4.4.1 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)
11.1.2.4.4.2 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)
11.1.2.4.4.3 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)
11.1.2.4.4.4 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)
11.1.2.4.5 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)
11.1.2.4.6 South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)
11.1.2.5 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)
11.1.2.5.1 Overview
11.1.2.5.2 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)
11.1.2.5.3 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million)
11.1.2.5.4 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, by Structures, 2019–2028 (US$ Million)
11.1.2.5.4.1 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)
11.1.2.5.4.2 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)
11.1.2.5.4.3 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)
11.1.2.5.4.4 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)
11.1.2.5.5 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)
11.1.2.5.6 Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)
11.1.2.6 Rest of Asia Pacific: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
11.1.2.6.1 Overview
11.1.2.6.2 Rest of Asia Pacific: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
11.1.2.6.3 Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million)
11.1.2.6.4 Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, by Structures, 2019–2028 (US$ Million)
11.1.2.6.4.1 Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)
11.1.2.6.4.2 Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)
11.1.2.6.4.3 Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)
11.1.2.6.4.4 Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)
11.1.2.6.5 Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)
11.1.2.6.6 Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)
12. Glycomic Therapeutics Market –Industry Landscape
12.1 Overview
12.2 Growth Strategies in the Glycomic Therapeutics Market (%)
12.3 Organic Developments
12.3.1 Overview
12.4 Inorganic Developments
12.4.1 Overview
13. Company Profiles
13.1 BioMarin Pharmaceutical Inc.
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Genzyme Corporation (Sanofi)
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Bayer AG
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 GlaxoSmithKline plc.
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 F. Hoffmann-La Roche Ltd
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms in Glycomic Therapeutics Market

LIST OF TABLES

Table 1. Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, (US$ Million).
Table 2. Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million).
Table 3. Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)
Table 4. Asia Pacific: Glycomic Therapeutics Market, by Structures – Revenue and Forecast to 2028 (US$ Million)
Table 5. Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)
Table 6. Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)
Table 7. Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)
Table 8. Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)
Table 9. Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)
Table 10. China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million).
Table 11. China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, by Structures – Revenue and Forecast to 2028 (US$ Million)
Table 12. China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)
Table 13. China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)
Table 14. China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)
Table 15. China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)
Table 16. China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)
Table 17. China: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)
Table 18. Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million).
Table 19. Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, by Structures – Revenue and Forecast to 2028 (US$ Million)
Table 20. Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)
Table 21. Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)
Table 22. Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)
Table 23. Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)
Table 24. Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)
Table 25. Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)
Table 26. India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million).
Table 27. India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, by Structures – Revenue and Forecast to 2028 (US$ Million)
Table 28. India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)
Table 29. India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)
Table 30. India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)
Table 31. India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)
Table 32. India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)
Table 33. India: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)
Table 34. South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million).
Table 35. South Korea: Glycomic Therapeutics Market, by Structures – Revenue and Forecast to 2028 (US$ Million)
Table 36. South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)
Table 37. South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)
Table 38. South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)
Table 39. South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)
Table 40. South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)
Table 41. South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)
Table 42. Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million).
Table 43. Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, by Structures – Revenue and Forecast to 2028 (US$ Million)
Table 44. Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)
Table 45. Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)
Table 46. Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)
Table 47. Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)
Table 48. Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)
Table 49. Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)
Table 50. Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Class (US$ Million).
Table 51. Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, by Structures – Revenue and Forecast to 2028 (US$ Million)
Table 52. Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Sialic Acid (US$ Million)
Table 53. Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosaminoglycans (US$ Million)
Table 54. Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Targeting Glycosphingolipids (US$ Million)
Table 55. Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Others (US$ Million)
Table 56. Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Indications (US$ Million)
Table 57. Rest of Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Mode of Action (US$ Million)
Table 58. Organic Developments in the Glycomic Therapeutics Market
Table 59. Inorganic Developments in the Glycomic Therapeutics Market
Table 60. Glossary of Terms in Glycomic Therapeutics Market

LIST OF FIGURES

Figure 1. Asia Pacific Glycomic Therapeutics Market Segmentation
Figure 2. Asia Pacific Glycomic Therapeutics Market, By Country
Figure 3. Asia Pacific Glycomic Therapeutics Market Overview
Figure 4. Synthetic Segment Held Largest Share of Class Segment in Asia Pacific Glycomic Therapeutics Market
Figure 5. India is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. Asia Pacific: PEST Analysis
Figure 7. Asia Pacific Glycomic Therapeutics Market Impact Analysis of Driver and Restraints
Figure 8. Asia Pacific Glycomics market – Revenue Forecast And Analysis – 2020- 2028
Figure 9. Asia Pacific Glycomic Therapeutics Market, by Class 2022 & 2028 (%)
Figure 10. Asia Pacific Isolated Revenue and Forecasts to 2028 (US$ Million)
Figure 11. Asia Pacific Synthetic – Revenue and Forecasts to 2028 (US$ Million)
Figure 12. Asia Pacific Glycomics Market, by Indication 2022 & 2028 (%)
Figure 13. Asia Pacific Thrombosis and chemoprophylaxis Revenue and Forecasts to 2028 (US$ Million)
Figure 14. Asia Pacific Anaemia Revenue and Forecasts to 2028 (US$ Million)
Figure 15. Asia Pacific Anti-adhesive and Anti-inflammatory Revenue and Forecasts to 2028 (US$ Million)
Figure 16. Asia Pacific Cataract Revenue and Forecasts to 2028 (US$ Million)
Figure 17. Asia Pacific Gaucher’s diseases Revenue and Forecasts to 2028 (US$ Million)
Figure 18. Asia Pacific MPS-1 & IV Revenue and Forecasts to 2028 (US$ Million)
Figure 19. Asia Pacific Cancer Revenue and Forecasts to 2028 (US$ Million)
Figure 20. Asia Pacific Alzheimer’s Revenue and Forecasts to 2028 (US$ Million)
Figure 21. Asia Pacific Influenza Type A and B Revenue and Forecasts to 2028 (US$ Million)
Figure 22. Asia Pacific Others Revenue and Forecasts to 2028 (US$ Million)
Figure 23. Asia Pacific Glycomic Therapeutics Market, by Structures 2022 & 2028 (%)
Figure 24. Asia Pacific Glycoproteins – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 25. Asia Pacific Targeting Sialic Acid – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 26. Asia Pacific Zanamivir – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 27. Asia Pacific Oseltamivir – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 28. Asia Pacific Proteoglycans – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 29. Asia Pacific Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin Based Glycans – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 30. Asia Pacific Targeting Glycosaminoglycans – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 31. Asia Pacific Heparin – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 32. Asia Pacific Hyaluronan (HA)- Market Revenue and Forecasts to 2028 (US$ Million)
Figure 33. Asia Pacific Laronidase – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 34. Asia Pacific Galsulfase (Naglazyme) – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 35. Asia Pacific Hyaluronidase (Cumulase) – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 36. Asia Pacific Others – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 37. Asia Pacific Targeting Glycosphingolipids – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 38. Asia Pacific Imiglucerase (Cerezyme) – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 39. Asia Pacific Agalsidase (Fabrazyme) – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 40. Asia Pacific N-butyl-deoxynojirimycin (DNJ) – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 41. Asia Pacific Others – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 42. Asia Pacific Others – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 43. Asia Pacific Acarbose – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 44. Asia Pacific Alglucosidase Alfa (Myozyme) – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 45. Asia Pacific Allosamidin – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 46. Asia Pacific Others – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 47. Asia Pacific Glycomic Therapeutics Market, by Mode of Action 2022 & 2028 (%)
Figure 48. Asia Pacific Inhibits Neuraminidase – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 49. Asia Pacific Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 50. Asia Pacific Erythropoietin And Enzyme Replacement Therapy (ERT) – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 51. Asia Pacific Tissue Plasminogen Activator – Market Revenue And Forecasts To 2028 (US$ Million)
Figure 52. Asia Pacific Inhibits Glucosylceramide Synthase – Market Revenue And Forecasts To 2028 (US$ Million)
Figure 53. Asia Pacific Interleukin 1 And 2 And 3- Market Revenue And Forecasts To 2028 (US$ Million)
Figure 54. Asia Pacific Beta And Gamma Interferons – Market Revenue And Forecasts To 2028 (US$ Million)
Figure 55. Asia Pacific Others – Market Revenue And Forecasts To 2028 (US$ Million)
Figure 56. Asia Pacific: Glycomic Therapeutics Market Overview, by Country (2022)
Figure 57. Asia Pacific: Glycomic Therapeutics Market Revenue and Forecasts to 2028, By Country (%)
Figure 58. China: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)
Figure 59. Japan: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)
Figure 60. India: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)
Figure 61. South Korea: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)
Figure 62. Australia: Glycomic Therapeutics Market Revenue and Forecasts to 2028 (US$ Million)
Figure 63. Rest of Asia Pacific: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 64. Growth Strategies in the Glycomic Therapeutics Market (%)

● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific Glycomic Therapeutics Market.
● Highlights key business priorities in order to assist companies to realign their business strategies.
● The key findings and recommendations highlight crucial progressive industry trends in Asia Pacific Glycomic Therapeutics Market, thereby allowing players across the value chain to develop effective long-term strategies.
● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
● Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the market, as well as those hindering it.
● Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

The List of Companies – Asia Pacific Glycomic Therapeutics Market

● BioMarin Pharmaceutical Inc.                    
● Genzyme Corporation (Sanofi)                 
● Bayer AG                                                            
● GlaxoSmithKline plc.         
● F. Hoffmann-La Roche Ltd           

At 17.8% CAGR, the Asia Pacific Glycomic Therapeutics Market is speculated to be worth US$ 34.59 billion by 2028, says The Insight Partners

According to The Insight Partners’ research, the Asia Pacific glycomic therapeutics market was valued at US$12.95 billion in 2022 and is expected to reach US$ 34.59 billion by 2028, registering an annual growth rate of 17.8% from 2022 to 2028. Wide application in various disorders followed by the development of new treatment processes and increasing research and development in the field of glycomic therapeutics are the critical factors attributed to the market expansion.

Glycan-based products have wide applications in the therapeutic industry, the products are available in different structures & forms and developed as per the application. This drug is designed for various diseases, such as thrombosis, anemia, cancer, influenza, cataract, anti-inflammation, and various others. The glycoprotein is a type of glycan can be used to deliver drugs, toxins, or radioactive substances directly to cancer cells. Monoclonal antibodies, including erythropoietin (EPO) and Herceptin (trastuzumab), are widely used and are part of several research projects. These products are aimed at expanding and improving their applicability and efficacy. EPO has been used to treat traumatic brain injury (TBI) in young patients and Alzheimer’s disease in rodent models due to its known neuroprotective effects. The largest and fastest-growing application category is drug discovery and development, mostly due to the rise in R&D by pharmaceutical and biotechnology firms and the expansion of drug discovery research activities in university research institutions. For instance, In March 2021, 48Hour Discovery (48HD) and CQDM announced that the firms received an award of US$ 800,000 for peptide drug development utilizing its unique drug discovery platform. The CQDM Quantum Leap initiative, which encourages research into cutting-edge technologies, methods, and platforms that speed up or expedite drug discovery and development, provided funding for the two-year study. Merck, a CQDM member, is financing the study. The University of Alberta and 48HD will work together on the project. In December 2021, researchers at Griffith University’s Institute for Glycomics received US$ 2.6 million funding from the Australian Cancer Research Foundation (ACRF) to establish the ACRF International Centre for Cancer Glycomics as a boost in their fight against cancer.Researchers at Kaleido Biosciences are developing therapeutics for immune-mediated and inflammatory diseases with synthetic glycans that are selectively metabolized in the gut microbiome to suppress the growth of bacteria associated with inflammation. One synthetic glycan candidate, KB295, is intended to treat ulcerative colitis, an inflammatory bowel disorder (IBD). The administration of microbiome-mediating glycans could radically improve treatment by 16% of IBD sufferers who do not respond to the current standard of care and other patients with hard-to-treat autoimmune and inflammatory conditions.These advancements show that glycomics has the potential to provide rapid and accurate therapeutic results for complex conditions. Therefore, the use of glycomics in drug development for diseases across the world drives the glycomics therapeutics market.

On the contrary, high cost of equipment hampers market Asia Pacific glycomic therapeutics market.

Based on class, the market is segmented into isolated and synthetic. The synthetic segment held 53.63% market share in 2022, amassing US$ 6.95 billion. It is projected to garner US$ 18.20 billion by 2028 to expand at 17.4% CAGR during 2022–2028. Based on structure, the market is segmented into glycoproteins, targeting sialic acid, proteoglycans, targeting glycosaminoglycans, glycosylphosphatidylinositol (GPI)anchored proteins & heparin based glycans, targeting glycosphingolipids, and others. The glycoproteins segment held 52.45% market share in 2022, amassing US$ 6.79 billion. It is projected to garner US$ 18.44 billion by 2028 to expand at 18.1% CAGR during 2022–2028. Based on indications, the market is segmented into thrombosis & chemoprophylaxis, anaemia, anti-adhesive & anti-inflammatory, cataracts, Gaucher’s disease, mps-1 & iv,cancer, alzheimer’s disease, influenza type a & b, and others. The influenza type a & b segment held 37.65% market share in 2022, amassing US$ 4.88 billion. It is projected to garner US$ 12.99 billion by 2028 to expand at 17.7% CAGR during 2022–2028. Based on mode of action, the market is segmented into inhibits neuraminidase, inhibits heparanase and selectins and blocks interactions between growth factors and heparan sulfate, erythropoietin & enzyme replacement therapy (ERT), tissue plasminogen activator, inhibits glucosylceramide synthase, interleukin 1 and 2 and 3, beta & gamma interferons, and others. The erythropoietin & enzyme replacement therapy (ERT) segment held 39.40% market share in 2022, amassing US$ 5.10 billion. It is projected to garner US$ 13.44 billion by 2028 to expand at 17.5% CAGR during 2022–2028. Based on country, the Asia Pacific glycomic therapeutics market has been categorized into China ,Japan ,India ,Australia, South Korea and Rest of Asia Pacific. Our regional analysis states that China captured 29.25% market share in 2022. It was assessed at US$ 3.79 billion in 2022 and is likely to hit US$ 10.01 billion by 2028, exhibiting a CAGR of 17.6% during the forecast period. Key players dominating the Asia Pacific glycomic therapeutics market are BioMarinPharmaceuticalInc.;GenzymeCorporation(Sanofi);BayerAG;Alzheon,Inc.;GlaxoSmithKline plc.;F. Hoffmann-La Roche Ltd..

In May,2022; Halozyme Therapeutics announced the completion of its acquisition of Antares Pharma, Inc. The acquisition aims to create specialty products. In May,2021; Alzheon, Inc. announced that it has entered into a collaboration and license agreement with the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB) to develop the first clinical assay to measure neurotoxic beta-amyloid (amyloid, A?) oligomers in human cerebrospinal fluid (CSF). Under the collaboration agreement, IOCB applied Alzheon’s technology for detecting oligomers into a customized clinical assay in human CSF, to be developed by the IOCB and commercialized by Alzheon.